HLS Therapeutics (TSE:HLS) Trading 0.2% Higher - Here's Why

Key Points

• HLS Therapeutics shares traded up 0.2% to C$4.65 (intraday high C$4.71) on light volume of 7,500 shares, about 15% below average, and the stock sits just below its 200‑day moving average (C$4.77) while above its 50‑day (C$4.46).
• The company reported negative earnings (C($0.05) EPS last quarter), a negative ROE (−19.4%) and net margin (−22.34%), with quarterly revenue of C$20.06M and analysts forecasting roughly −0.12 EPS for the year.
• HLS is a specialty pharmaceutical focused on CNS and cardiovascular products, with a market cap of C$145.42M, relatively high leverage (debt‑to‑equity 80.79) and modest liquidity (quick ratio 1.01, current ratio 1.11).

HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s stock price traded up 0.2% on Tuesday . The stock traded as high as C$4.71 and last traded at C$4.65. 7,500 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 8,815 shares. The stock had previously closed at C$4.64.

HLS Therapeutics Trading Up 0.2%

The company's fifty day moving average is C$4.46 and its two-hundred day moving average is C$4.77. The company has a debt-to-equity ratio of 80.79, a quick ratio of 1.01 and a current ratio of 1.11. The company has a market cap of C$145.42 million, a price-to-earnings ratio of -11.92 and a beta of 0.34.

HLS Therapeutics (TSE:HLS - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported C($0.05) earnings per share for the quarter. HLS Therapeutics had a negative return on equity of 19.40% and a negative net margin of 22.34%.The business had revenue of C$20.06 million during the quarter. On average, research analysts anticipate that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.